| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Meta-Analysis; Review; Systematic Review
- Language: English
- [Inflammopharmacology] 2022 Apr; Vol. 30 (2), pp. 435-451. <i>Date of Electronic Publication: </i>2022 Feb 21.
- MeSH Terms: Spondylitis, Ankylosing* / drug therapy ; Antibodies, Monoclonal / therapeutic use ; Antibodies, Monoclonal, Humanized ; Humans ; Interleukin Inhibitors
- References: Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Sieper J (2011) Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthr Res Ther 13(3):1–9. ; Babaie F, Hasankhani M, Mohammadi H, Safarzadeh E, Rezaiemanesh A, Salimi R, Babaloo Z (2018) The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. Immunol Lett 196:52–62. https://doi.org/10.1016/j.imlet.2018.01.014. (PMID: 29409751) ; Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, Van der Heijde D, Wordsworth P (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. The Lancet 382(9906):1705–1713. ; Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Andersson M (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548. (PMID: 26699169) ; Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36(1):50–55. (PMID: 28516874) ; Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Fierlinger A (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5(2):e001005. (PMID: 315652446744073) ; Braun J, Sieper J (2007) Ankylosing spondylitis. The Lancet 369(9570):1379–1390. ; Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Richards HB (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077. (PMID: 27965257) ; Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Porter B (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology 58(5):859–868. (PMID: 30590813) ; Chen W-S, Chang Y-S, Lin K-C, Lai C-C, Wang S-H, Hsiao K-H, Chou C-T (2012) Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 75(7):303–308. (PMID: 22824043) ; Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Jung JW (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206(2):299–311. (PMID: 192041112646568) ; Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Gandhi KK (2019a) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269. (PMID: 30148436) ; Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Lee EB (2019b) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthr Rheumatol 71(4):599–611. ; Deodhar A, van der Heijde D, Gensler LS, Kim T-H, Maksymowych WP, Østergaard M, Tomita T (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. The Lancet 395(10217):53–64. ; Dinauer MC (2016) Primary immune deficiencies with defects in neutrophil function. Hematol Am Soc Hematol Educ Prog. https://doi.org/10.1182/asheducation-2016.1.43. ; Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J (2002) Conventional treatments for ankylosing spondylitis. Annl Rheum Dis 61(Suppl 3):40–50. https://doi.org/10.1136/ard.61.suppl_3.iii40. ; Dougados M, Wei JC-C, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Tomita T (2020) Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 79(2):176–185. (PMID: 31685553) ; Erdes S, Nasonov E, Kunder E, Pristrom A, Soroka N, Shesternya P, Krechikova D (2019) Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol 38:27–34. (PMID: 31025924) ; Goldman L, Schafer AI (2011) Goldman's cecil medicine E-book: Elsevier Health Sciences. ; Han Q, Das S, Hirano M, Holland SJ, McCurley N, Guo P, Cooper MD (2015) Characterization of lamprey IL-17 family members and their receptors. J Immunol 195(11):5440–5451. (PMID: 26491201) ; Higgins J (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 The Cochrane Collaboration. www. cochrane-handbook. org. ; Hwang S-Y, Kim J-Y, Kim K-W, Park M-K, Moon Y, Kim W-U, Kim H-Y (2004) IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB-and PI3-kinase/Akt-dependent pathways. Arthr Res Ther 6(2):1–9. ; Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136(12):896–907. (PMID: 12069564) ; Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S (2020) Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Mod Rheumatol 30(1):132–140. (PMID: 30334633) ; Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, Porter B (2018) Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther 5(2):447–462. (PMID: 301218276251842) ; Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Group MS (2017) Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthr Care Res 69(7):1020–1029. ; McAleer JP, Kolls JK (2011) Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol 90(2):263–270. (PMID: 214869053133441) ; Miossec P, Kolls JK (2012) Targeting IL-17 and TH 17 cells in chronic inflammation. Nat Rev Drug Discov 11(10):763–776. (PMID: 23023676) ; Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Porter B (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthr Res Ther 19(1):285. ; Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H (2005) C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 11(2):101–108. (PMID: 15679483) ; Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Audry M (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332(6025):65–68. (PMID: 213501223070042) ; Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Guyatt GH (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349:g5630. (PMID: 25252733) ; Rezaiemanesh A, Abdolmaleki M, Abdolmohammadi K, Aghaei H, Pakdel FD, Fatahi Y, Nicknam MH (2018) Immune cells involved in the pathogenesis of ankylosing spondylitis. Biomed Pharmacother 100:198–204. https://doi.org/10.1016/j.biopha.2018.01.108. (PMID: 29428668) ; Rudwaleit M, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Dougados M (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783. (PMID: 1929734419297344) ; Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou C, Kirazli Y (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31. (PMID: 21109520) ; Schwarzenberger P, Huang W, Ye P, Oliver P, Manuel M, Zhang Z, Kolls JK (2000) Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol 164(9):4783–4789. (PMID: 10779785) ; Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. The Lancet 390(10089):73–84. ; Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Maksymowych W (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annl Rheum Dis 68(Suppl 2):ii1–ii44. ; Song X, He X, Li X, Qian Y (2016) The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol 13(4):418–431. (PMID: 270182184947810) ; Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. (PMID: 20652370) ; Taams LS, Steel KJ, Srenathan U, Burns LA, Kirkham BW (2018) IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol 14(8):453–466. (PMID: 30006601) ; van der Heijde D, Wei JC-C, Dougados M, Mease P, Deodhar A, Maksymowych WP, Landewé R (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. The Lancet 392(10163):2441–2451. ; van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, Coarse J (2020) Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis 79(5):595–604. (PMID: 32253184) ; Veldhoen M (2017) Interleukin 17 is a chief orchestrator of immunity. Nat Immunol 18(6):612. (PMID: 28518156) ; Wendling D, Cedoz J-P, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74(3):304–305. (PMID: 17369068) ; Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Weng X (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res 7:22. https://doi.org/10.1038/s41413-019-0057-8. (PMID: 316669976804882)
- Contributed Indexing: Keywords: Ankylosing spondylitis (AS); Immune-related adverse events (irAEs); Interleukin (IL)-17 inhibitors; Randomized controlled trial (RCT)
- Substance Nomenclature: 0 (Antibodies, Monoclonal) ; 0 (Antibodies, Monoclonal, Humanized) ; 0 (Interleukin Inhibitors) ; D3IAG45DAK (netakimab)
- Entry Date(s): Date Created: 20220221 Date Completed: 20220328 Latest Revision: 20220401
- Update Code: 20231215
|
